A federal-register-style document folder and notebook on a sunlit desk, representing a careful review of cannabis policy As of November 13, 2026, what schedule is cannabis? The short answer depends on the product and its legal pathway: adult-use cannabis generally remains Schedule I under federal law, while qualifying state-licensed medical marijuana and FDA-approved marijuana products moved to Schedule III on April 28, 2026. A separate federal proceeding could move cannabis more broadly to Schedule III, but it is not finished and has not changed the schedule for adult-use products. Here, we explain what the schedules mean, what changed in 2026, and what remains uncertain, so readers can make informed decisions without confusing a pending proposal with current law.

How the Controlled Substances Act schedules work

The Controlled Substances Act (CSA) divides controlled substances into five schedules. Federal officials consider a substance’s abuse potential, whether it has a currently accepted medical use in the United States, and its safety under medical supervision. In broad terms, Schedule I is defined by high abuse potential, no currently accepted medical use, and a lack of accepted safety under medical supervision. Schedule II substances also have high abuse potential, but have accepted medical use, or accepted use with severe restrictions, and may lead to severe psychological or physical dependence. Schedule III substances have less abuse potential than Schedule I and II substances, have accepted medical use, and may lead to moderate or low physical dependence or high psychological dependence. Schedules IV and V generally involve lower abuse potential than the schedule immediately above them, with accepted medical use and progressively lower dependence risks. These categories are legal classifications, not a complete scientific account of a substance’s effects or risks. A change in schedule alters the federal controls that apply; it does not automatically mean a product is FDA-approved, available by prescription, or legal for every use.

Schedule I vs. Schedule II vs. Schedule III

  • Schedule I: High abuse potential, no currently accepted medical use under the CSA criteria, and no accepted safety under medical supervision. Cannabis outside the qualifying exceptions described below remains here.
  • Schedule II: High abuse potential, accepted medical use (sometimes with severe restrictions), and potential for severe dependence.
  • Schedule III: Lower abuse potential than Schedules I and II, accepted medical use, and potential for moderate or low physical dependence or high psychological dependence. Qualifying medical marijuana and FDA-approved marijuana products were placed here in 2026.

The categories carry different regulatory consequences, but Schedule III is still a controlled-substance schedule. Rescheduling is not the same thing as descheduling or federal legalization.

How does a drug get moved between schedules?

Under the standard CSA process, the Department of Health and Human Services (HHS) provides a medical and scientific evaluation. The Food and Drug Administration (FDA) conducts that review for HHS, and the DEA Administrator considers the evaluation and other required factors before making findings. The DEA can then issue a proposed rule, invite public comment, and publish a final rule or order. A scheduling review may also begin through a petition, action by the Attorney General, or legislation passed by Congress; the precise legal pathway can vary. For the statutory criteria, see 21 U.S.C. § 812, which establishes the schedules, and 21 U.S.C. § 811, which addresses scheduling authority and procedures.

Is weed a Schedule I drug?

Yes, at the federal level, for adult-use or recreational cannabis. In everyday terms, the answer to “is weed a Schedule 1 drug?” remains yes for adult-use products as of November 13, 2026. There are important exceptions. Since April 28, 2026, FDA-approved drug products containing marijuana and marijuana covered by qualifying state-issued medical marijuana licenses have been placed in Schedule III under a DOJ order. That does not mean every product sold at a dispensary is FDA-approved, or that every state-licensed medical business automatically has federal registration. The distinction matters: qualifying medical businesses must meet federal requirements, including applicable DEA registration and controls. Cannabis that falls outside the order, including adult-use products, remains subject to Schedule I controls. A researcher reviewing notes beside glass labware in a softly lit workspace

What Schedule I has meant in practice

Research: Schedule I status has historically created extra steps for cannabis researchers. Research involving controlled substances requires appropriate DEA registration and compliance with federal rules, including requirements in 21 CFR Part 1301; for years, researchers also encountered a narrow supply system associated with NIDA’s cannabis program. The 2026 medical order may create new pathways for qualifying work, but it does not remove controlled-substance oversight. Banking: Banks serving cannabis businesses have faced compliance and due-diligence burdens under the Bank Secrecy Act. FinCEN guidance describes expectations for financial institutions, but it does not erase their reporting obligations or make every cannabis transaction federally lawful. Taxes: Section 280E of the federal tax code has restricted ordinary business deductions for businesses trafficking in Schedule I or II substances. The move of qualifying medical marijuana to Schedule III changes the 280E picture for medical operators, while adult-use operators remain affected; read our 280E explainer for more detail. State and federal law: A state license does not, by itself, override federal law or provide a general federal criminal defense for activity outside the CSA’s exceptions. The medical registration pathway applies only to qualifying activity and businesses that meet the relevant federal conditions. Federal employment and firearms: Federal employees, service members, veterans, and people who use cannabis may face separate workplace, service, or benefit policies. Federal firearms law, including 18 U.S.C. § 922(g)(3), also raises issues for some people who use controlled substances; how it applies can depend on the facts and evolving court decisions. This is a complex area where individual legal advice matters.

Track one, the law that already changed

The first track is finished law. A DOJ order effective April 28, 2026 moved FDA-approved marijuana products and marijuana products covered by qualifying state medical marijuana licenses from Schedule I to Schedule III. It did not move all cannabis, and it did not move adult-use marijuana to Schedule III. A further implementation step came on October 30, 2026, when DOJ announced that DEA had begun issuing its first federal registrations to more than 900 qualifying state-licensed medical marijuana dispensaries in Alabama, Florida, Mississippi, South Dakota, Texas, Virginia, and West Virginia. These dispensaries must meet federal requirements, including security, recordkeeping, and inventory controls; state licensure alone is not federal registration. DEA also set November 29, 2026 as a supply-chain compliance deadline for “Timely Applicants” to verify trading partners and establish compliant supply chains. That date is still in the future as of this article’s publication, and businesses should consult current DEA instructions for details. The DOJ’s April 2026 announcement describes the medical scheduling order; the October registration announcement explains the initial dispensary registrations and the limits of that pathway.

Track two, the hearing that is not law yet

A separate administrative proceeding considers whether all cannabis should move from Schedule I to Schedule III. The evidentiary phase has ended, and final reply briefs were submitted on November 5, 2026, after a brief pause to consider a Government Accountability Office report. Chief Administrative Law Judge Derek Julius is preparing a recommendation for DEA Administrator Terry Cole. That recommendation will be nonbinding; the Administrator must make the final decision, and any final order could still face court challenges. As of November 13, there is no deadline for the recommendation and no final order broadly rescheduling cannabis. Adult-use cannabis therefore remains Schedule I federally while this proceeding continues. The DEA’s drug-scheduling information is one place to check for official updates.

Why the two tracks are easy to confuse

Both tracks involve Schedule III, and both have produced major federal announcements in 2026. But one is an effective order covering defined medical categories; the other is a separate, unfinished proceeding that could address cannabis more broadly. That means headlines saying “cannabis is Schedule III” can leave out the most important detail: which cannabis, under which authority, and as of what date? The medical change is in effect within its defined scope; broader rescheduling is not law.

What this means for patients

For patients, the April order created a federal framework for qualifying medical marijuana activity, and the October registrations show that some dispensaries have begun entering it. Registered businesses can operate under federal Schedule III controls, subject to requirements such as inventory, security, and recordkeeping. The change may also allow qualifying medical operators to move beyond the tax restrictions of 280E, though tax treatment can depend on business activities and IRS guidance. It does not make every dispensary federally registered or mean that every medical product is an FDA-approved medicine. A patient speaking with a staff member across a welcoming dispensary counter

What this means for adult-use consumers

For adult-use consumers, the broad federal picture has not changed: adult-use cannabis remains Schedule I. The medical order does not authorize recreational marijuana, and a state-legal dispensary selling adult-use products is not thereby federally authorized to sell them. Do not assume state legality allows interstate transport or resolves restrictions involving airports, federal land, or other federal settings. Rules and enforcement can vary by context, and crossing state lines with cannabis can raise serious legal risks.

How federal scheduling connects to state law

Federal scheduling and state cannabis laws are separate layers, and a state can legalize cannabis without moving it on the federal schedule. Our state-by-state guide to where cannabis is legal covers that map in detail, but nothing on it changes the federal schedule described here.

The takeaway

The most accurate answer to “what schedule is cannabis?” in November 2026 is: Schedule I for adult-use cannabis, and Schedule III for qualifying state-licensed medical marijuana and FDA-approved marijuana products. The separate proposal to move cannabis more broadly to Schedule III remains pending, so the phrase “cannabis is Schedule III now” needs context. We aim to share science-backed information, break down myths, and foster a stigma-free place to learn. Because federal scheduling is actively moving, verify current details through the DEA, 21 U.S.C. § 812, the relevant DOJ announcements, and the Federal Register. This article is for educational purposes and reflects information available as of November 13, 2026. It is not legal advice; consult a qualified attorney about your circumstances.